Abstract: A composition for improving the solubility of poorly soluble substances is provided. The composition for improving the solubility of poorly soluble substances includes 60-97% by weight of cyclodextrin and/or a derivative thereof, 0.5-4% by weight of at least one water-soluble polymer and 0.4-30% by weight of at least one water-soluble stabilizer, wherein the at least one water-soluble stabilizer includes caffeine, and wherein the poorly soluble substance is a tyrosine kinase inhibitor.

Abstract: A composition for improving the solubility of poorly soluble substances is provided. The composition includes about 40-99.5% by weight of cyclodextrin and/or derivatives thereof; about 0.05-10% by weight of at least one water-soluble polymer; and about 0.05-60% by weight of at least one water-soluble stabilizer.

Abstract: An immunostimulatory lipoplex is provided. The immunostimulatory lipoplex includes a liposome and at least one immunostimulatory nucleic acid drug, and the immunostimulatory nucleic acid drug is complexed with the liposome The liposome includes 40 to 85 mol % of cationic lipid, 10 to 50 mol % of cholesterol, and 0.001 to 20 mol % of modified polyethylene glycol lipid.

Abstract: A contact lens with sustained-release property is provided. The contact lens includes a polymer, pseudorotaxane embedded in the polymer, and a stabilizer embedded in the pseudorotaxane. The polymer is polymerized by monomer materials. The monomer materials include ethyl methacrylate, ethylene glycol dimethacrylate, methacrylic acid, 2-hydroxyethyl methacrylate, or a combination thereof. The stabilizer includes surfactant, amino acid with a polar side chain, oligopeptide containing at least one amino acid with a polar side chain, purine or its derivative, or a combination thereof.

Abstract: A hydrogel composition is provided. The hydrogel composition includes polyglutamic acid (PGA) containing maleimide groups, and polyethylene glycol (PEG) containing terminal thiol groups, wherein the hydrogel composition has a pH value ranging from 4.0 to 6.5. A drug delivery system is also provided. The drug delivery system includes the above-mentioned hydrogel composition, and a pharmaceutically active ingredient encapsulated in the hydrogel composition.

Abstract: A composition for improving the solubility of poorly soluble substances is provided. The composition includes about 40-99.5% by weight of cyclodextrin and/or derivatives thereof; about 0.05-10% by weight of at least one water-soluble polymer; and about 0.05-60% by weight of at least one water-soluble stabilizer.

Abstract: An object of the present invention is to provide a method for producing a microcapsule formulation using a biodegradable polymer, the method being capable of avoiding direct contact of a peptidic physiologically active substance with an organic solvent layer, and achieving a high encapsulation efficiency of the peptidic physiologically active substance.

Abstract: A hydrogel composition is provided. The hydrogel composition includes polyglutamic acid (PGA) containing maleimide groups, and polyethylene glycol (PEG) containing terminal thiol groups, wherein the hydrogel composition has a pH value ranging from 4.0 to 6.5. A drug delivery system is also provided. The drug delivery system includes the above-mentioned hydrogel composition, and a pharmaceutically active ingredient encapsulated in the hydrogel composition.

Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.

Abstract: [Object] An object of the present invention is to provide a method for producing a microcapsule formulation using a biodegradable polymer, the method being capable of avoiding direct contact of a peptidic physiologically active substance with an organic solvent layer, and achieving a high encapsulation efficiency of the peptidic physiologically active substance.

Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.